“Synthetic gp90 peptide ELISA for equine infectious anemia virus: Improved sensitivity and risk factor insights”.

Overview

• This study developed a new diagnostic test using a synthetic peptide-based ELISA to detect equine infectious anemia virus (EIAV) in horses.
• The new ELISA showed better sensitivity compared to the existing standard AGID test and helped identify risk factors for EIAV infection.

Background

• Equine infectious anemia virus (EIAV) is a serious infectious disease affecting horses worldwide.
• EIAV control depends on effective surveillance through serological testing, i.e., detecting antibodies in horse blood.
• Currently, the World Organization for Animal Health (WOAH) recommends the agar gel immunodiffusion (AGID) test as the standard diagnostic tool.
• The AGID test, however, has limitations, particularly in sensitivity, which means it can miss some infected horses, especially those with low antibody levels.

Objective

• The study aimed to develop and validate an improved indirect ELISA assay using a synthetic peptide from a conserved portion of the EIAV gp90 surface glycoprotein.
• Gp90 is a viral protein that is highly antigenic and conserved across virus strains, making it a good target for antibody detection.
• The goal was to achieve better sensitivity to detect more infected horses including those with subclinical infections.

Methods

• Developed an indirect ELISA using a synthetic peptide representing a conserved region of the gp90 protein.
• Sampled 773 horse sera from the Metropolitan Zone of the Valley of Mexico to evaluate the ELISA performance.
• Compared the ELISA results with the standard AGID test results to assess sensitivity, specificity, and agreement.
• Conducted statistical analyses including sensitivity, specificity, kappa coefficient (κ) for agreement, and p-values for significance.
• Performed risk factor analysis and cluster analysis to identify groups of horses with higher infection rates and geographic clustering of cases.

Results

• The gp90 peptide-based ELISA showed a sensitivity of 85.3%, meaning it correctly identified 85.3% of actual positive cases.
• Its specificity was 97.9%, meaning it correctly identified 97.9% of negative cases.
• The ELISA identified 29.4% more seropositive horses than the AGID test, showing superior detection ability (statistically significant with p = 0.044).
• The agreement between ELISA and AGID was substantial, with a kappa statistic of 0.73.
• Risk factor analysis revealed higher risk in horses younger than 4 years old.
• Cluster analysis showed that infections were geographically concentrated in temperate climate zones with summer rains.

Conclusions

• The synthetic gp90 peptide indirect ELISA is a more sensitive and effective tool for screening EIAV infection compared to AGID.
• It allows earlier detection of subclinical infections that AGID might miss, improving surveillance and control efforts.
• Identification of high-risk groups based on age and geographic factors can help target monitoring and preventive measures.
• Implementing this ELISA could lead to better EIAV surveillance programs by enabling earlier, more accurate identification of infected horses and reducing virus transmission.